WeedHeadLines

DEA Reaffirms Stance That CBD Meets Schedule I Criteria — Reality Says Otherwise

 Breaking News
  • Marijuana is NORML: 45% of Americans Have Tried Cannabis According to recently released polling data from Gallup, nearly half of all Americans have tried marijuana at one point in their lives, an all time high since they began asking the question in 1969 when only 4% of Americans admitted to having tried the substance. Additionally, 12% of survey respondents said they currently consume marijuana. Gallup concludes: “With 29 U.S. states allowing medical marijuana use, and eight allowing recreational use, legal cannabis is taking hold in American society. There may be obstacles to marijuana becoming fully “accepted” in the United States. Attorney General Sessions appears to be cracking down on marijuana use, and driving under the influence of pot continues to be a concern for many. Despite legal hurdles, however, a record-high percentage of Americans say they have tried marijuana.Smoking pot is still not as prevalent as cigarette smoking in the U.S., at 17%, but current marijuana usage is about as high as it has been. If more states legalize the drug, regular usage — or at least experimenting with marijuana — could rise. Legality may confer a certain societal acceptance of the drug. Sessions’ hopes to prosecute state-level marijuana crimes may prove to be a hindrance, but it is unlikely this multibillion-dollar industry will be stopped anytime soon.” Read the full survey results here....
  • Colorado: Tax Revenue From The Legal Cannabis Industry Surpasses Half-Billion Dollars Revenues from Colorado’s legal cannabis industry have surpassed over a half-billion dollars since retail sales began on January 1, 2014. According to an analysis by VS Strategies, cannabis-related taxes and fees have yielded $506,143,635 in new state revenue over the past three and one-half years. (Local tax revenue was excluded from the analysis.) Much of the revenue raised has gone to fund school construction projects, school-drop out and substance abuse prevention programs, and grant funding. The half-billion dollar total far exceeds initial projections. Tax revenue from legal cannabis sales in Oregon and Washington have also exceeded regulators’ initial expectations. In Nevada, where retail sales to adult became legal on July 1, retailers reported over 40,000 transactions in just the first weekend....
  • Uruguay: Retail Cannabis Sales Begin Today Select pharmacies in Uruguay are now dispensing marijuana to adults, under regulations that went into effect today. Sixteen pharmacies are presently licensed to engage in cannabis sales, and some 5,000 adults so far have registered with the state to purchase marijuana products — which are capped at a price of $1.30 per gram. Sales to foreign tourists are not permitted under the law. Federal officials initially approved legislation in 2013 lifting the state’s criminal prohibition of the plant. Under the policy change, citizens may cultivate up to six plants per household, and engage in collective cultivation as part of membership clubs. Rules and regulations governing the distribution of marijuana for medical purposes are overseen by the Ministry of Public Health. ...
  • WATCH: Marijuana in the Halls of Congress! Yesterday, NORML moderated a Facebook Congressional Conversation on marijuana law reform with Representatives Earl Blumenauer, Tom Garrett, Beto O’Rourke, and Justin Amash. We discussed a wide range of issues including the needless burden of the federal driver’s license suspension mandate, access to medical marijuana, racial injustice, and pending bipartisan legislation to remove cannabis from the Controlled Substances Act. WATCH NOW: Share on Facebook | Share on Twitter The ongoing enforcement of cannabis prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, impedes legitimate scientific research into the plant’s medicinal properties, and disproportionately impacts communities of color. Only when lawmakers speak honestly about the effects of prohibition and the senseless burdens it imposes on our communities will we be able to win substantial reform. In our continued effort to educate the lawmakers and the public, events like this will be able to open the eyes of those who have willfully ignored the issue. NORML chapters throughout the country are working to advance legalization in state legislatures and, with your support, National NORML will continue to up the pressure in Washington, DC. Click here to share the video through your networks and support efforts like this in the future. ...
  • WATCH: Marijuana in the Halls of Congress Yesterday, NORML moderated a Facebook Congressional Conversation on marijuana law reform with Representatives Earl Blumenauer, Tom Garrett, Beto O’Rourke, and Justin Amash. We discussed a wide range of issues including the needless burden of the federal driver’s license suspension mandate, access to medical marijuana, racial injustice, and pending bipartisan legislation to remove cannabis from the Controlled Substances Act. WATCH NOW: Share on Facebook | Share on Twitter The ongoing enforcement of cannabis prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, impedes legitimate scientific research into the plant’s medicinal properties, and disproportionately impacts communities of color. Only when lawmakers speak honestly about the effects of prohibition and the senseless burdens it imposes on our communities will we be able to win substantial reform. “At a time when 29 states and the District of Columbia have made the decision to regulate the sale and use of marijuana, we should rethink how the federal government approaches this drug. Our current approach to marijuana prevents legitimate medical use, fills our prisons with nonviolent offenders and continues to fuel drug violence,” said Representative Beto O’Rourke in a statement promoting the event. In our continued effort to educate the lawmakers and the public, events like this will be able to open the eyes of those who have willfully ignored the issue. NORML chapters throughout the country are working to advance legalization in state legislatures and, with your support, National NORML will continue to up the pressure in Washington, DC. Click here to share the video through your networks and support efforts like this in the future. ...

DEA Reaffirms Stance That CBD Meets Schedule I Criteria — Reality Says Otherwise

July 10
22:25 2017

DEA Reaffirms Stance That CBD Meets Schedule I Criteria — Reality Says Otherwise

  • by Paul Armentano, NORML Deputy Director
    July 10, 2017
    Comments

    oil_bottlesThe US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”

    The agency has long contended that CBD, along with all organic cannabinoids, is — by default — a schedule I controlled substance because it is a naturally occurring component of the cannabis plant. (This position is similarly held by both the NIDA and the FDA.) Nonetheless, a growing body of science undermines the notion that CBD meets any of the criteria necessary for such classification.

    Specifically, clinical trial data finds that CBD is “safe,” “non-toxic,” and “well tolerated” in human volunteers. Even the director of the US National Institute on Drug Abuse acknowledges that CBD is “not mind-altering” and that it “appears to be a safe drug with no addictive effects.”

    Recently conducted controlled studies also acknowledge its therapeutic efficacy, particularly the ability of CBD dosing to mitigate treatment-resistant seizures, hypertension, and psychotic symptoms in humans. Other peer-reviewed data shows that CBD therapy holds promise for the treatment of “Parkinson’s disease, Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer.”

    That is why in addition to the thirty states that presently recognize medical cannabis, an additional 16 states also explicitly recognize the use of CBD as a viable medical treatment.

    Nonetheless, it remains unlikely that the DEA is going to amend its position any time soon. Further, police in recent months have begun initiating raids of CBD retailers, such as those reported here, here, and here. That is why it is critical that members of Congress move forward with legislation to remove the cannabis plant from the Controlled Substances Act.

    Presently, several pieces of federal legislation are pending to amend the federal classification of CBD as a schedule I substance. These include:

    HR 2020: Passage of this act would exclude CBD from the federal definition of ‘marihuana.’

    S. 1374/HR 2920: Passage of these Acts would exempt from federal prosecution those who are engaged in state-sanctioned medical cannabis activities; it would also remove CBD from the federal definition of ‘marihuana.’

    HR 2273/S. 1008: Passage of these Acts would exclude CBD and CBD-rich cannabis plants from the federal definition of ‘marihuana.’

    You can contact your members of Congress in support of these bills and other pending legislation by visiting NORML’s Take Action Center here.

    Tags : cannabidiol, CBD, DEA, Schedule I
    Posted in : SCIENCE
    Add Your Comment

Share

Related Articles

0 Comments

No Comments Yet!

There are no comments at the moment, do you want to add one?

Write a comment

Write a Comment